Secondary outcome: quality of life · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: acceptability of treatment · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Costs · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome: prevention of ulcer · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ulcer healing · ulceration and other skin changes caused by nerve damage in leprosy
1 finding from 1 review
Resource implications (e.g. cost of incontinence management methods) · children aged 3 to 17 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life measurements · children aged 3 to 17 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · children aged 3 to 17 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resolution of daytime urinary incontinence · children aged 5 to 16 years with daytime urinary incontinence
Voiding education with uroflow feedback and urotherapy showed no clear difference in resolution of daytime urinary incontinence at 6 to 12 months after 6… compared with urotherapy alone (low certainty).
1 finding from 1 review
Frequency of incontinence episodes · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Objective measurement of volume of incontinent episodes · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life measurements · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · children aged 5 to 16 years with daytime urinary incontinence
1 finding from 1 review
Resolution of daytime urinary incontinence · children aged 3 to 17 years with daytime urinary incontinence
It is very uncertain whether pelvic floor muscle training (PFMT) with urotherapy changes resolution of daytime urinary incontinence after 12 months of… compared with urotherapy alone (very low certainty).
1 finding from 1 review
Frequency of incontinence episodes · children aged 3 to 17 years with daytime urinary incontinence
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Objective measurement of volume of incontinent episodes · children aged 3 to 17 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Smoking cessation · people who smoke
Reduction and pharmacotherapy may leads to higher main analysis (all pharmacotherapy): smoking cessation (≥ 6 month compared with reduction alone (low certainty).
1 finding from 1 review
Subgroup: combination NRT; smoking cessation (≥ 6 month · people who smoke
Reduction and pharmacotherapy showed no clear difference in subgroup: combination NRT; smoking cessation (≥ 6 month compared with reduction alone (low certainty).
1 finding from 1 review
Subgroup: nicotine patch; smoking cessation (≥ 6 month · people who smoke
It is very uncertain whether reduction and pharmacotherapy changes subgroup: nicotine patch; smoking cessation (≥ 6 month compared with reduction alone (very low certainty).
1 finding from 1 review